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Abstract 
Characterization of a hyperthermophilic redox protein, rubredoxin, as a 
potential targeted cancer therapeutic 
Siri Lakshmi Chirumamilla 
M.S., May 2012 
Philadelphia College of Osteopathic Medicine 
Francis E. Jenney, Jr, Thesis Adviser 
Cancer is an elusive neoplastic disease that claims the lives of many 
people around the world every year. Though treatments have become more 
specific to the different types of cancer, the need remains for antineoplastic drugs 
that target cancer cells and leave normal cells unharmed, with little to no 
systemic toxicity. The search for a targeted cancer therapeutic is necessary and 
urgent, and Pyrococcus furiosus rubredoxin might be such a tool. Rubredoxin is a 
small (53 amino acids), water soluble, non-heme iron electron transfer protein 
that contains an iron atom cofactor bound by the sulfurs of four cysteine 
residues, which contribute to the redox activity of this protein. Rubredoxin from 
the hyperthermophile Pyrococcus furiosus is thermostable and appears to have 
low immunogenicity. The focus of this project was to incorporate tumor specific 
binding sequences at the central loop, express, and purify these recombinant 
rubredoxin proteins. Next, the wild-type and recombinant rubredoxins were 
characterized based on absorption spectra, thermostability, metal content, and 
antibody affinity. Lastly, the effect of wild-type and recombinant rubredoxins 
was assessed on cancer cells in-vitro. 
The Pyrococcus furiosus rubredoxin gene was manipulated via site-directed 
mutagenesis to incorporate two test epitopes (E-tag and RGD-tag) at the central 
loop (between D20 and N21 position). The mutant proteins (D20-Etag and D20-
RGD) were purified and analyzed using absorption spectroscopy, 
thermostability, SDS-PAGE, electrospray ionization mass spectroscopy (ESI-MS), 
ii 
and inductively coupled mass spectrometry (ICP-MS). Binding studies for the 
D20-Etag mutant were done using a dot blot. Lastly, integrin-stimulated Jurkat 
cancer cells were incubated with wild-type rubredoxin, D20-Etag, D20-RGD, and 
the cells were assayed for apoptosis via gel electrophoresis at 24 and 48 hour 
time points. 
The E-tag epitope was successfully incorporated between the D20 and 
N21 amino acid residues using site directed mutagenesis. The D20-Etag and D20-
RGD mutant rubredoxin proteins were successfully expressed, purified, and 
analyzed. There was an apoptotic effect of D20-RGD rubredoxin on the Jurkat 
cell line. These results provided a further understanding and appreciation of 
rubredoxin as a potential targeted therapeutic to cancer cells. 
